Pills

This is the text extract for Schedule Update - effective 1 October 2013, browse documents here.


Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 October 2013

Cumulative for September and October 2013


Contents

Summary of PHARMAC decisions effective 1 October 2013 .......................... 3 New treatment for amyotrophic lateral sclerosis (motor neurone disease).... 4 Further information on the definition of Specialist ....................................... 4 Clopidogrel – stock delay .............................................................................. 5 Permax – temporary out-of-stock .................................................................. 5 Pramipexole – supply issues .......................................................................... 5 News in brief ................................................................................................. 5 Tamoxifen – new packsize ............................................................................. 6 Cyclophosphamide – new brand ................................................................... 6 Tender News .................................................................................................. 7 Looking Forward ........................................................................................... 7 Sole Subsidised Supply products cumulative to October 2013 ...................... 8 New Listings ................................................................................................ 18 Changes to Restrictions, Chemical Names and Presentations ...................... 21 Changes to Subsidy and Manufacturer’s Price............................................. 26 Changes to General Rules............................................................................ 28 Delisted Items ............................................................................................. 29 Items to be Delisted .................................................................................... 31 Index ........................................................................................................... 32

2


Summary of PHARMAC decisions

EFFECTIVE 1 OCTOBER 2013 New listings (pages 18-19) • Clopidogrel (Arrow - Clopid) tab 75 mg • Enalapril maleate (Ethics Enalapril) tab 5 mg, 10 mg and 20 mg • Hydralazine hydrochloride (Apresoline s29) inj 20 mg ampoule – S29 • Tamsulosin hydrochloride (Tamsulosin-Rex) cap 400 mcg – Special Authority – Retail pharmacy • Riluzole (Rilutek) tab 50 mg – Special Authority – Retail pharmacy • Maprotiline hydrochloride (Ludiomil s29) tab 75 mg, 20 tab pack – S29 • Cyclophosphamide (Procytox) tab 50 mg – PCT – Retail pharmacy – Specialist – S29 • Tamoxifen citrate (Genox) tab 10 mg and 20 mg – new pack sizes • Loratadine (Lorafix) tab 10 mg Changes to restrictions, chemical names and presentation (page 21) • Enalapril maleate tab 5 mg, 10 mg and 20 mg – addition of STAT dispensing • Perindopril (Coversyl) – Removal of higher subsidy by endorsement • Zoledronic acid (Aclasta) soln for infusion 5 mg in 100 ml – addition of OP • Oxycodone hydrochloride (OxyNorm) cap immediate-release 5 mg, 10 mg and 20 mg – amend presentation • Hyoscine (Scopolamine) (Scopoderm TTS) – Change to chemical name Decreased subsidy (page 26) • Clotrimazole (Clomazol) vaginal crm 2 % with applicators, 20 g OP • Oxycodone hydrochloride (OxyContin) tab controlled-release 10 mg, 20 mg, 40 mg and 80 mg Increased subsidy (page 26) • Clotrimazole (Clomazol) vaginal crm 1 % with applicators, 35 g OP • Cefaclor monohydrate (Ranbaxy-Cefaclor) cap 250 mg

3


4 Pharmaceutical Schedule - Update News

New treatment for amyotrophic lateral sclerosis (motor neurone disease)

Riluzole (Rilutek) 50 mg tablets will be listed from 1 October 2013 subject to Special Authority criteria for patients with amyotrophic lateral sclerosis. The wastage rule will be applied to riluzole.

Further information on the definition of Specialist

From 1 September 2013 the definition of Specialist changed to include all vocational scopes approved by the Medical Council of New Zealand. Where a Pharmaceutical Schedule listing specifies that a Specialist must be of a particular vocational scope, the treatment will only be subsidised if a Specialist with a specified vocational scope endorses or recommends this treatment. For example, itraconazole 100 mg capsules are subsidised for tinea vesicolor. Where it is used for other indications, it will only be subsidised on the recommendation from an infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist. A vocationally registered general practitioner cannot authorise the subsidy of itraconazole 100 mg capsules. Where a Special Authority specifies that the applicant is a Specialist of a particular vocational scope, then only the specified Specialist can make that application for their patient. For example, a gastroenterologist must make the initial application for the Special Authority for adalimumab in the treatment of Crohn’s disease. Any practitioner may apply for the renewal of the Special Authority on the recommendation of a gastroenterologist.


Pharmaceutical Schedule - Update News

5

Clopidogrel – stock delay

Actavis New Zealand Ltd has advised that there has been a delay to the arrival of stock of its brand of clopidogrel tab 75 mg, (Arrow-Clopid). Actavis now expects that stock will be available from early October; however the brand will still be listed from 1 October 2013 as previously notified. The Apotex brand remains listed and will be reference priced from 1 December 2013.

Permax – temporary out-of-stock

The Permax brand of pergolide tab 0.25 mg and tab 1 mg is likely to remain out-of-stock until January 2014. This follows further manufacturing issues. No other brand of this pharmaceutical is available and patients should see their prescriber for advice.

Pramipexole – supply issues

Dr Reddy's New Zealand Ltd has advised that it is discontinuing supply of its brand of pramipexole (Dr Reddy’s Pramipexole). Stock of the tab 0.125 mg is no longer available, while remaining stock of the tab 0.25 mg and tab 0.5 mg have an expiry of November 2013. Stock of the tab 1 mg has an expiry of April 2014. PHARMAC is working to identify an alternative supplier and hopes to make an announcement soon.

News in brief

• From 1 October 2013, Original Pack (OP) dispensing will be applied to Aclasta (zoledronic acid) 5 mg in 100 ml infusion. • The Movicol brand of macrogol 3350 powder 13.125 g, sachet will be delisted 1 December 2013. Stock of the Lax-Sachets brand is now available. Sole supply will be reinstated on the Lax-Sachets brand from 1 December 2013. • Dr Reddy’s has advised that all presentations of its risperidone tablets are now back in stock. • The Dr Reddy’s brand of ondansetron 4 mg dispersible tablets (4 tab pack) will be delisted on 1 April 2014. The 10 tablet pack will remain listed. • The Budenocort brand of budesonide powder for inhalation, 200 mcg and 400 mcg per dose will be delisted from 1 April 2014.


6

Pharmaceutical Schedule - Update News

Tamoxifen – new packsize

Mylan has advised that stock of its currently listed packs of tamoxifen (Genox tab 10 mg and 20 mg 100 tab packsize) may be in short supply for a few weeks following a production delay. Mylan has sourced alternative packsizes of Genox which will be listed fully funded from 1 October 2013. Please refer to page 19 for further details.

Cyclophosphamide – new brand

The Cycloblastin brand of cyclophosphamide tab 50 mg has been discontinued by the supplier and stock will be exhausted from late October 2013. This is an essential medicine for a small group of patients. We have sourced an alternative product from Clinect, Procytox tab 50 mg 100 pack, which will be listed, fully subsidised, from 1 October 2013. Procytox is approved overseas but is not registered in New Zealand, therefore, must be supplied in accordance with section 29 of the Medicines Act 1981. The wastage rule will be applied to the Procytox brand.


Tender News

Sole Subsidised Supply changes – effective 1 November 2013

Chemical Name Bupropion hydrochloride Cefalexin monohydrate Cefalexin monohydrate Cefalexin monohydrate Clindamycin Colchicine Haloperidol Haloperidol Haloperidol Haloperidol Haloperidol Hydrocortisone Indapamide Itraconazole Mercaptopurine Mitomycin C Sulphasalazine Sulphasalazine Zidovudine [AZT] Zidovudine [AZT] Presentation; Pack size Tab modified-release 150 mg; 30 tab Cap 500 mg; 20 cap Grans for oral liq 125 mg per 5 ml; 100 ml Grans for oral liq 250 mg per 5 ml; 100 ml Cap hydrochloride 150 mg; 16 cap Tab 500 mcg; 100 tab Tab 500 mcg; 100 tab Tab 1.5 mg; 100 tab Tab 5 mg; 100 tab Oral liq 2 mg per ml; 100 ml Inj 5 mg per ml, 1 ml; 10 inj Inj 100 mg vial; 1 inj Tab 2.5 mg; 90 tab Cap 100 mg; 15 cap Tab 50 mg; 25 tab Inj 5 mg vial; 1 inj Tab 500 mg; 100 tab Tab EC 500 mg; 100 tab Cap 100 mg; 100 cap Oral liq 10 mg per ml; 200 ml OP Sole Subsidised Supply brand (and supplier) Zyban (GSK) Cephalexin ABM (ABM) Cefalexin Sandoz (Sandoz) Cefalexin Sandoz (Sandoz) Clindamycin ABM (ABM) Colgout (Aspen) Serenace (Aspen) Serenace (Aspen) Serenace (Aspen) Serenace (Aspen) Serenace (Aspen) Solu-Cortef (Pfizer) Dapa-Tabs (Mylan) Itrazole (Mylan) Puri-nethol (Aspen) Arrow (Arrow) Salazopyrin (Pfizer) Salazopyrin EN (Pfizer) Retrovir (GSK) Retrovir (GSK)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for future implementation 1 November 2013 • Methotrexate (Methotrexate Sandoz) inj 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg prefilled syringe – new listing. • Paroxetine hydrochloride (Loxamine) – new 90 tab pack size.

7


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Abacavir sulphate Acarbose Acetazolamide Acetylcysteine Aciclovir Allopurinol Amantadine hydrochloride Aminophylline Amiodarone hydrochloride Amisulpride Amitriptyline Amlodipine Amoxycillin Amoxycillin clavulanate

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 50 mg and 100 mg Tab 250 mg Inj 200 mg per ml, 10 ml Tab dispersible 200 mg, 400 mg & 800 mg Tab 100 mg & 300 mg Cap 100 mg Inj 25 mg per ml, 10 ml Inj 50 mg per ml, 3 ml ampoule Oral liq 100 mg per ml Tab 100 mg, 200 mg & 400 mg Tab 10 mg Tab 25 mg & 50 mg Tab 2.5 mg Tab 5 mg & 10 mg Inj 250 mg, 500 mg & 1 g Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab 500 mg with potassium clavulanate 125 mg Crm Tab 50 mg & 100 mg Tab 10 mg, 20 mg, 40 mg & 80 mg Inj 600 mcg, 1 ml Tab 500 mg Tab 10 mg Tab 2.5 mg & 5 mg Inj 1.2 mega u per 2.3 ml Inj 600 mg Eye drops 0.5% Eye drops 0.25%

Brand Name Expiry Date*

Ziagen Ziagen Accarb Diamox Martindale Acetylcysteine Lovir Apo-Allopurinol Symmetrel DBL Aminophylline Cordarone-X Solian Arrow-Amitriptyline Amitrip Apo-Amlodipine Apo-Amlodipine Ibiamox Augmentin Augmentin Curam Duo AFT Mylan Atenolol Zarator AstraZeneca Apo-Azithromycin Pacifen ArrowBendrofluazide Bicillin LA Sandoz Betoptic Betoptic S 2014 2014 2015 2015 2015 2015 2016 2014 2015 2014 2014 2014 2015 2014 2015 2016 2014 2014 2014 2016 2016 2014 2014 2014 2015

Aqueous cream Atenolol Atorvastatin Atropine sulphate Azithromycin Baclofen Bendrofluazide Benzathine benzylpenicillin Benzylpenicillin sodium (Penicillin G) Betaxolol hydrochloride

8

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Bezafibrate Bicalutamide Blood glucose diagnostic test meter Blood glucose diagnostic test strip Boceprevir Brimonidine tartrate Cabergoline Calamine Calcitonin Calcium carbonate Calcium folinate Candesartan Carbomer Cefazolin sodium Cefuroxime sodium Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate

Presentation

Tab 200 mg Tab long-acting 400 mg Tab 50 mg Meter with 50 lancets, a lancing device and 10 diagnostic test strips Blood glucose test strips Cap 200 mg Eye drops 0.2% Tab 0.5 mg Lotn, BP Inj 100 iu per ml, 1 ml Tab 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental) Tab 15 mg Tab 4 mg, 8 mg, 16 mg & 32 mg Ophthalmic gel 0.3%, 0.5 g Inj 500 mg & 1 g Inj 750 mg Oral liq 1 mg per ml Tab 10 mg Eye oint 1% Eye drops 0.5% Mouthwash 0.2% Handrub 1% with ethanol 70% Soln 4% Nail-soln 8% Tab 0.5 mg, 2.5 mg & 5 mg Tab 250 mg, 500 mg & 750 mg Tab 20 mg Tab 500 mg Tab 250 mg Inj phosphate 150 mg per ml, 4 ml Tab 50 mg Tab 10 mg & 25 mg Tab 25 mcg Tab 150 mcg Inj 150 mcg per ml, 1 ml

Brand Name Expiry Date*

Bezalip Bezalip Retard Bicalaccord CareSens N CareSens N POP CareSens II CareSens CareSens N Victrelis Arrow-Brimonidine Dostinex PSM Miacalcic Arrow-Calcium Calsource DBL Leucovorin Calcium Candestar Poly-Gel AFT Multichem Cetirizine - AFT Zetop Chlorsig Chlorafast healthE healthE Orion Apo-Ciclopirox Zapril Cipflox Arrow-Citalopram Apo-Clarithromycin Apo-Clarithromycin Dalacin C Serophene Apo-Clomipramine Clonidine BNM Catapres 2015 2014 2015

2015 2016 2014 2015 2015 2014 2014 2014 2015 2016 2014 2014 2014 2015 2015 2014 2015 2016 2014 2014 2014 2016 2016 2015 2015

Ciclopirox olamine Cilazapril Ciprofloxacin Citalopram hydrobromide Clarithromycin Clindamycin Clomiphene citrate Clomipramine hydrochloride Clonidine hydrochloride

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

9


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Clotrimazole Codeine phosphate Crotamiton Cyclizine hydrochloride Cyclosporin Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone

Presentation

Crm 1% Tab 15 mg, 30 mg & 60 mg Crm 10% Tab 50 mg Oral liq 100 mg per ml Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs Nasal spray 10 mcg per dose Tab 1 mg & 4 mg Eye oint 0.1%

Brand Name Expiry Date*

Clomazol PSM Itch-Soothe Nausicalm Neoral Siterone Ginet 84 Desmopressin-PH&T Douglas Maxidex Maxitrol Maxitrol 2014 2016 2015 2015 2015 2015 2014 2014 2015 2014 2014

Dexamethasone with neomycin Eye oint 0.1% with neomycin sulphate and polymyxin b sulphate 0.35% and polymyxin B sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Dexamphetamine sulphate Dextrose Diclofenac sodium Tab 5 mg Inj 50%, 10 ml Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Inj 25 mg per ml, 3 ml Eye drops 1 mg per ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab 30 mg & 60 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 10 mg Tab 2 mg & 4 mg Tab 100 mg Oint BP Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Inj 500 mcg per ml, 1 ml Tab 200 mg

PSM Biomed Apo-Diclo Diclax SR Voltaren Voltaren Ophtha Voltaren DHC Continus Apo-Diltiazem CD Dilzem Pytazen SR Laxofast 50 Laxofast 120 Prokinex Apo-Doxazosin Doxine AFT Clexane Entapone DBL Ergometrine Arrow-Etidronate

2015 2014 2015 2014

Dihydrocodeine tartrate Diltiazem hydrochloride

2016 2015

Dipyridamole Docusate sodium Domperidone Doxazosin mesylate Doxycycline hydrochloride Emulsifying ointment Enoxaparin sodium Entacapone Ergometrine maleate Etidronate disodium

2014 2014 2015 2014 2014 2014 2015 2015 2014 2015

10

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Ethinyloestradiol Ethinyloestradiol with levonorgestrel

Presentation

Tab 10 mcg Tab 20 mcg with levonorgestrel 100 mcg & 7 inert tab Tab 30 mcg with levonorgestrel 150 mcg & 7 inert tab Tab 25 mg Tab long-acting 5 mg & 10 mg Tab long-acting 2.5 mg Inj 50 mcg per ml, 2 ml & 10 ml Inj 300 mcg per 0.5 ml Inj 480 mcg per 0.5 ml Tab 5 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 250 mg & 500 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Eye drops 0.1% Crm 5% Metered aqueous nasal spray, 50 mcg per dose Tab 500 mg Tab 40 mg Oint 2% Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Suppos 3.6 g Aerosol spray 400 mcg per dose TDDS 5 mg & 10 mg Tab 600 mcg Tab 5 mg & 20 mg Crm 1% Powder Rectal foam 10%, CFC-Free (14 applications) Lipocream 0.1% Milky emul 0.1% Oint 0.1% Scalp lotn 0.1%

Brand Name Expiry Date*

NZ Medical and Scientific Ava 20 ED Ava 30 ED Aromasin Plendil ER Plendil ER Boucher and Muir Zarzio Zarzio Rex Medical AFT Staphlex Flucloxin Ozole Flucon Efudix Flixonase Hayfever & Allergy Urex Forte Diurin 40 Foban Pfizer Apo-Gliclazide Minidiab PSM Glytrin Nitroderm TTS Lycinate Douglas Pharmacy Health ABM Colifoam Locoid Lipocream Locoid Crelo Locoid Locoid 2014 2015 2015

31/12/15

2015 2014

Exemestane Felodopine Fentanyl Filgrastim Finasteride Flucloxacillin sodium

2014 2015 2014 2014 2015 2015 2015 2015 2016 2015 2014 2015 2015 2014

Fluconazole Fluorometholone Fluorouracil sodium Fluticasone propionate Furosemide Fusidic acid Gentamicin sulphate Gliclazide Glipizide Glycerol Glyceryl trinitrate

Hydrocortisone

2015 2014 2015 2015

Hydrocortisone acetate Hydrocortisone butyrate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

11


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hyoscine N-butylbromide Ibuprofen Imiquimod Ipratropium bromide

Presentation

Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Inj 20 mg, 1 ml Tab 10 mg Tab 200 mg Tab long-acting 800 mg Crm 5% Nebuliser soln, 250 mcg per ml, 1 ml Nebuliser soln, 250 mcg per ml, 2 ml Inj 50 mg per ml, 2 ml Tab 100 mg Tab 20 mg Tab long-acting 40 mg Cap 10 mg & 20 mg Powder for oral soln Shampoo 2% Tab 100 mg Cap 15 mg & 30 mg Eye drops 50 mcg per ml Tab 2.5 mg Tab 1.5 mg Subdermal implant (2 x 75 mg rods) Inj 2% ampoule, 5 ml & 20 ml Viscous soln 2% Tab 5 mg, 10 mg & 20 mg Tab 250 mg & 400 mg Cap 250 mg Eye drops 0.1% Tab 12.5 mg, 25 mg, 50 mg & 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml

Brand Name Expiry Date*

DP Lotn HC ABM Hydroxocobalamin Plaquenil Buscopan Gastrosoothe Arrowcare Brufen SR Aldara Univent 2014 2015 2015 2014 2014 2014 2016

Iron polymaltose Isoniazid Isosorbide mononitrate Isotretinoin Ispaghula (psyllium) husk Ketoconazole Lamivudine Lansoprazole Latanoprost Letrozole Levonorgestrel Lidocaine [lignocaine] hydrochloride Lisinopril Lithium carbonate Lodoxamide trometamol Losartan Losartan with hydrochlorothiazide Macrogol 400 and propylene glycol

Ferrum H PSM Ismo 20 Corangin Oratane Konsyl-D Sebizole Zetlam Solox Hysite Letraccord Postinor-1 Jadelle Lidocaine-Claris Xylocaine Viscous Arrow-Lisinopril Lithicarb FC Douglas Lomide Lostaar Arrow-Losartan & Hydroclorothiazide Systane Unit Dose

2014 2015 2014 2015 2016 2014 2014 2015 2015 2015 2016 31/12/13 2015 2014 2015 2015 2014 2014 2014 2014 2016

12

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Mask for spacer device Mebendazole Mebeverine hydrochloride Medroxyprogesterone acetate Megestrol acetate Methotrexate Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Mesalazine Metformin hydrochloride Methadone hydrochloride

Presentation

Size 2 Tab 100 mg Tab 135 mg Tab 2.5 mg, 5 mg, 10 mg & 100 mg Inj 150 mg per ml, 1 ml syringe Tab 160 mg Inj 25 mg per ml, 2 ml & 20 ml Tab 4 mg & 100 mg Inj 40 mg per ml Inj 40 mg per ml with lignocaine 1 ml Enema 1 g per 100 ml Suppos 500 mg Tab immediate-release 500 mg & 850 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 40 mg per ml, 1 ml; 62.5 mg per ml, 2 ml; 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab 10 mg Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg Inj 1 mg per ml, 5 ml Tab 50 mg & 100 mg Tab long-acting 200 mg Oral gel 20 mg per g Crm 2% Tab 30 mg & 45 mg Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml

Brand Name Expiry Date*

EZ-fit Paediatric Mask De-Worm Colofac Provera Depo-Provera Apo-Megestrol Hospira Medrol Depo-Medrol Depo-Medrol with Lidocaine Pentasa Asacol Apotex Biodone Biodone Forte Biodone Extra Forte Solu-Medrol Pfizer Metamide Metoprolol-AFT CR Lopresor Lopresor Slow-Lopresor Decozol Multichem Avanza Apo-Moclobemide m-Mometasone RA-Morph 2015 2014 2014 2016 2015 2016 2015 2015 2015 2015 2014 2015 2015

Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol succinate Metoprolol tartrate

2015 2014 2015 2015

Miconazole Miconazole nitrate Mirtazapine Moclobemide Mometasone furoate Morphine hydrochloride

2015 2014 2015 2015 2015 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

13


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Morphine sulphate

Presentation

Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg Inj 5 mg per ml, 1 ml Inj 10 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Inj 30 mg per ml, 1 ml

Brand Name Expiry Date*

Arrow-Morphine LA DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate Hospira Naltraccord Naphcon Forte Apo-Nadolol Noflam 250 Noflam 500 AstraZeneca Nevirapine Alphapharm Habitrol Habitrol Habitrol Apo-Nicotinic Acid Noriday 28 Primolut N Arrow-Norfloxacin Norpress Nilstat Octreotide Max Rx 2014 2015 2014 2014 2016 2014 2014 2016 2014

Morphine tartrate Naltrexone hydrochloride Naphazoline hydrochloride Nadolol Naproxen Neostigmine Nevirapine Nicotine

Inj 80 mg per ml, 1.5 ml & 5 ml Tab 50 mg Eye drops 0.1% Tab 40 mg & 80 mg Tab 250 mg Tab 500 mg Inj 2.5 mg per ml, 1 ml Tab 200 mg Gum 2 mg & 4 mg (classic, fruit, mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 50 mg & 500 mg Tab 350 mcg Tab 5 mg Tab 400 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml Crm Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg Tab 10 mg & 15 mg Oral liq 5 mg per ml Tab 5 mg Inj 50 mg per ml, 1 ml Inj 10 mg per ml, 1 ml & 2 ml

2016 2016 2014 2015 2015 2014 2015 2014

Nicotinic acid Norethisterone Norfloxacin Nortriptyline hydrochloride Nystatin Octreotide (somatostatin analogue) Oil in water emulsion Omeprazole

healthE Fatty Cream Omezol Relief Midwest Dr Reddy’s Omeprazole Ox-Pam Apo-Oxybutynin OxyNorm Oxycodone Orion

2015 2014

Oxazepam Oxybutynin Oxycodone hydrochloride

2014 2016 2015

14

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Oxytocin Pamidronate disodium Pantoprazole Paracetamol

Presentation

Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Inj 3 mg per ml, 10 ml; 6 mg per ml, 10 ml & 9 mg per ml, 10 ml Inj 40 mg Suppos 500 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Low range & normal range Inj 135 mcg prefilled syringe & inj 180 mcg prefilled syringe Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 Tab 0.25 mg & 1 mg Crm 5% Lotn 5% Tab 50 mg & 100 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml

Brand Name Expiry Date*

Syntometrine Pamidronate BNM Pantocid IV Paracare Parafast Ethics Paracetamol Paracare Double Strength Paracetamol + Codeine (Relieve) Breath-Alert Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax Lyderm A-Scabies PSM DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride PSM Pizaccord Sandomigran Coloxyl Span-K Cholvastin Cilicaine Allersoothe Allersoothe 2014 2014 2015 2014 2015 2014 2014 2015 2014

Paracetamol with codeine Peak flow meter Pegylated interferon alfa-2a Pegylated interferon alfa-2a

2014 2015 2017 2017

Pergolide Permethrin Pethidine hydrochloride

Phenobarbitone Pioglitazone Pizotifen Poloxamer Potassium chloride Pravastatin Procaine penicillin Promethazine hydrochloride

Tab 15 mg & 30 mg Tab 15 mg, 30 mg & 45 mg Tab 500 mcg Oral drops 10% Tab long-acting 600 mg Tab 20 mg & 40 mg Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg

2015 2015 2015 2014 2015 2014 2014 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

15


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Pyridostigmine bromide Pyridoxine hydrochloride Quinapril Quinapril with hydrochlorothiazide

Presentation

Tab 60 mg Tab 25 mg Tab 50 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Cap 150 mg Tab 100 mg Tab orodispersible 10 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml & 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Tab 50 mg & 100 mg Tab 25 mg, 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Inj 23.4%, 20 ml ampoule Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Eye drops 1 mg per ml, 10 ml OP 800 ml 230 ml (single patient) Tab 25 mg & 100 mg Tab 50 mg & 100 mg Inj 12 mg per ml, 0.5 ml cartridge Tab 20 mg Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml Tab 10 mg Cap 5 mg, 20 mg, 100 mg & 250 mg

Brand Name Expiry Date*

Mestinon PyridoxADE Apo-Pyridoxine Arrow-Quinapril Accuretic 10 Accuretic 20 Peptisoothe Arrow-Ranitidine Mycobutin Norvir Rizamelt ArrowRoxithromycin Asthalin Duolin 2014 2016 2015 2014 2015 2015 2015 2014 2014 2015 2015

Ranitidine hydrochloride Rifabutin Ritonavir Rizatriptan Roxithromycin Salbutamol Salbutamol with ipratropium bromide Sertraline Sildenafil Simvastatin

Arrow-Sertraline Silagra Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg Biomed Micolette Hylo-Fresh Volumatic Space Chamber Plus Spirotone Arrow-Sumatriptan Genox Pinetarsol

2016 2014 2014

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium hyaluronate Spacer device Spironolactone Sumatriptan Tamoxifen citrate Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Temozolomide

2016 2016 2016 2015 2016 2016 2014 2014

Normison Temaccord

2014 2016

16

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to October 2013

Generic Name

Terazosin Terbinafine Testosterone cypionate Testosterone undecanoate Tetrabenazine Tetracosactrin Timolol maleate Tobramycin

Presentation

Tab 1 mg, 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Cap 40 mg Tab 25 mg Inj 250 mcg per ml, 1 ml ampoule Inj 1 mg per ml, 1 ml Eye drops 0.25% & 0.5% Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml Tab 100 mg Cap 50 mg Crm 0.5 mg per g Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP Eye drops 0.5% & 1% Cap 250 mg Inj 500 mg Tab 40 mg & 80 mg Tab 300 mg with lamivudine 150 mg Oint BP Caps 137.4 mg (50 mg elemental)

Brand Name Expiry Date*

Arrow Dr Reddy’s Terbinafine Depo-Testosterone Andriol Testocaps Motetis Synacthen Synacthen Depot Arrow-Timolol Tobrex Tobrex DBL Tobramycin Tasmar Arrow-Tramadol ReTrieve Kenacort-A Kenacort-A40 Aristocort Aristocort Oracort Mydriacyl Ursosan Mylan Isoptin Alphapharm Multichem Zincaps 2016 2014 2014 2015 2016 2014 2014 2014

Tolcapone Tramadol hydrochloride Tretinoin Triamcinolone acetonide

2014 2014 2016 2014

Tropicamide Ursodeoxycholic acid Vancomycin hydrochloride Verapamil hydrochloride Zidovudine [AZT] with lamivudine Zinc and castor oil Zinc sulphate October changes are in bold type

2014 2014 2014 2014 2014 2014 2014

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

17


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 October 2013

46 52 61 79 119 CLOPIDOGREL ❋ Tab 75 mg – For clopidogrel oral liquid formulation refer, page 189 .............................................................................. 5.48 ENALAPRIL MALEATE ❋ Tab 5 mg ................................................................................. 1.19 ❋ Tab 10 mg ............................................................................... 1.47 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 1.91 HYDRALAZINE HYDROCHLORIDE ❋ Inj 20 mg ampoule .................................................................. 25.90 84 100 100 100 ✔ Arrow - Clopid ✔ Ethics Enalapril ✔ Ethics Enalapril ✔ Ethics Enalapril

5

✔ Apresoline s29 S29 ✔ Tamsulosin-Rex ✔ Rilutek

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 – Retail pharmacy ❋ Cap 400 mcg .......................................................................... 13.51 100 RILUZOLE– Special Authority see SA1403 – Retail pharmacy – Wastage rule applies Tab 50 mg ............................................................................ 400.00 56

➽ SA1403 Special Authority for Subsidy Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and 3 The patient has not undergone a tracheostomy; and 4 The patient has not experienced respiratory failure; and 5 Any of the following: 5.1 The patient is ambulatory; or 5.2 The patient is able to use upper limbs; or 5.3 The patient is able to swallow. Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 The patient has not undergone a tracheostomy, and 2 The patient has not experienced respiratory failure; and 3 Any of the following: 3.1 The patient is ambulatory; or 3.2 The patient is able to use upper limbs; or 3.3 The patient is able to swallow. 123 MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 75 mg – wastage rule applies ........................................... 14.01 20 ✔ Ludiomil s29 S29 CYCLOPHOSPHAMIDE Tab 50 mg – PCT – Retail pharmacy-Specialist – wastage rule applies ....................................................... 158.00

147

100

✔ Procytox S29

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

18

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 October 2013 (continued)

160 176 TAMOXIFEN CITRATE ❋ Tab 10 mg ............................................................................... 2.63 ❋ Tab 20 mg ............................................................................... 2.63 Note – these are new packsizes with new Pharmacodes. LORATADINE ❋ Tab 10 mg ................................................................................ 1.30 60 30 ✔ Genox ✔ Genox

100

✔ Lorafix

Effective 1 September 2013

25 82 87 MESALAZINE Modified release granules, 1 g ............................................... 141.72 TETRACOSACTRIN ❋ Inj 250 mcg per ml, 1 ml ampoule ........................................... 17.71 DESMOPRESSIN Tab 100 mcg – Special Authority see SA1401 – Retail pharmacy................................................................ 36.40 Tab 200 mcg – Special Authority see SA1401 – Retail pharmacy................................................................ 93.60 120 g OP 1 ✔ Pentasa ✔ Synacthen

30 30

✔ Minirin ✔ Minirin

➽ SA1401 Special Authority for Subsidy Initial application (Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: 1. The patient has primary nocturnal enuresis; and 2. The nasal forms of desmopressin are contraindicated; and 3. An enuresis alarm is contraindicated. Initial application (Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: 1. The patient has cranial diabetes insipidus; and 2. The nasal forms of desmopressin are contraindicated Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. 98 BOCEPREVIR – Special Authority see SA1365 – Retail pharmacy – Wastage rule applies Cap 200 mg ....................................................................... 5,015.00 336 ✔ Victrelis ➽ SA1365 Special Authority for Subsidy Initial application — (chronic hepatitis C – genotype 1, first-line) from gastroenterologist, infectious disease physician or general physician Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has not received prior pegylated interferon treatment; and 3 Patient has IL-28B genotype CT or TT; and 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and 5 Patient is hepatitis C protease inhibitor treatment-naive; and 6 Maximum of 44 weeks therapy. Initial application — (chronic hepatitis C – genotype 1, second-line) from gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and continued... 2 Patient has received pegylated interferon treatment; and

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

19


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2013 (continued)

continued... 3 Any of the following: 3.1. Patient was a responder relapser; or 3.2. Patient was a partial responder; or 3.3. Patient received pegylated interferon prior to 2004; and 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and 5 Maximum of 44 weeks therapy. Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count <100 x109 /l or Albumin <35 g/l. Note: the wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly. 113 123 RISEDRONATE SODIUM Tab 35 mg ............................................................................... 4.00 4 ✔ Risedronate Sandoz

IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency – Wastage rule applies Tab 10 mg ................................................................................ 6.58 60 ✔ Tofranil S29 S29 THIOTEPA – PCT only – Specialist Inj 15 mg ............................................................................. CBS PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN ❋ Eye oint with soft white paraffin ................................................. 3.63 PHARMACY SERVICES – May only be claimed once per patient Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Acetec is 2445441

148

1 3.5 g OP 1 fee

✔ Tepadina S29 ✔ Refresh Night Time ✔ BSF Acetec

186 187

202

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (strawberry) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (vanilla) .......................................................................... 1.07 200 ml OP ✔ Pediasure Note – the packaging has changed to Recloseable Plastic Bottle (RPB) with new Pharmacodes. PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (vanilla) .......................................................................... 1.34 250 ml OP ✔ Pediasure

202

Effective 12 August 2013

52 ENALAPRIL MALEATE ❋ Tab 5 mg ................................................................................. 0.36 5.94 ❋ Tab 10 mg ............................................................................... 0.44 7.33 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 30 500 30 500 30 ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

20

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions, Chemical Names and Presentations

Effective 1 October 2013

52 ENALAPRIL MALEATE (addition of STAT dispensing) ❋ Tab 5 mg .................................................................................. 0.36 1.07 1.19 5.94 ❋ Tab 10 mg ................................................................................ 0.44 1.32 1.47 7.33 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 1.72 1.91 Note: the removal of the stat symbol will be temporary due to a stock recall 30 90 100 500 30 90 100 500 30 90 100 ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril ✔ Acetec ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril ✔ Acetec ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril

52

PERINDOPRIL (removal of subsidy by endorsement) From 1 August 2013 to 30 September 2013 the Coversyl brand of perindopril will be funded by Endorsement to the level of the ex-manufacturer price listed in the Schedule for patients who were previously accessing the higher subsidy by endorsement for perindopril prior to 1 May 2013. ❋ Tab 2 mg – Higher subsidy of up to $18.50 per 30 tab with Endorsement ......................................................................... 3.75 30 ✔ Apo-Perindopril (18.50) Coversyl ❋ Tab 4 mg – Higher subsidy of up to $25.00 per 30 tab with Endorsement ......................................................................... 4.80 30 ✔ Apo-Perindopril (25.00) Coversyl ZOLEDRONIC ACID – Special Authority see SA1187 – Retail pharmacy (addition of OP) Soln for infusion 5 mg in 100 ml ............................................ 600.00 100 ml OP ✔ Aclasta OXYCODONE HYDROCHLORIDE (amendment to presentation description) a) Only on a controlled drug form b) See prescribing guideline c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Cap immediate-release 5 mg .................................................. 2.83 Cap immediate-release 10 mg ................................................ 5.58 Cap immediate-release 20 mg ................................................ 9.77

115 122

20 20 20

✔ OxyNorm ✔ OxyNorm ✔ OxyNorm

130

HYOSCINE HYDROBROMIDE HYOSCINE (SCOPOLAMINE) – Special Authority see SA1387 – Retail pharmacy (change to chemical name) Patch 1.5 mg .......................................................................... 11.95 2 ✔ Scopoderm TTS

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

21


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013

52 ENALAPRIL MALEATE – Brand switch fee payable (Pharmacode 2445441) - see page 187 for details Tab 5 mg .................................................................................. 0.36 30 ✔ Acetec 1.07 90 ✔ m-Enalapril 5.94 500 ✔ Acetec Tab 10 mg ................................................................................ 0.44 30 ✔ Acetec 1.32 90 ✔ m-Enalapril 7.33 500 ✔ Acetec Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 30 ✔ Acetec 1.72 90 ✔ m-Enalapril Note: the removal of the stat symbol will be temporary due to a stock recall TETRACOSACTRIN (amendment to presentation) ❋ Inj 250 mcg per ml, 1 ml ampoule .......................................... 17.71 177.18 1 10 ✔ Synacthen ✔ Synacthen

82 106

Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment 1) Diagnosis • Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or • PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or • Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following. Exclusion Criteria 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease). 2) Pregnancy. 3) Neutropenia (<2.0 × 109) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alfa-2a alpha-2a or interferon alpha-2b alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months) Exit Criteria The patient’s response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pretreatment ALlevel at this stage. INTERFERON ALFA-2A ALPHA-2A – PCT – Retail pharmacy-Specialist (amendment to chemical name) a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 3 m iu prefilled syringe ....................................................... 31.32 1 ✔ Roferon-A Inj 6 m iu prefilled syringe ....................................................... 62.64 1 ✔ Roferon-A Inj 9 m iu prefilled syringe ....................................................... 93.96 1 ✔ Roferon-A

107

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

22

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

107 INTERFERON ALFA-2B ALPHA-2B – PCT – Retail pharmacy-Specialist (amendment to chemical name) a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 18 m iu, 1.2 ml multidose pen .......................................... 187.92 1 ✔ Intron-A Inj 30 m iu, 1.2 ml multidose pen .......................................... 313.20 1 ✔ Intron-A Inj 60 m iu, 1.2 ml multidose pen .......................................... 626.40 1 ✔ Intron-A PEGYLATED INTERFERON ALFA-2A ALPHA-2A – Special Authority see SA14001365 – Retail pharmacy See prescribing guideline Inj 135 mcg prefilled syringe ............................................... 1,448.00 4 Inj 180 mcg prefilled syringe .................................................. 900.00 4 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ......................................................... 1,159.84 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ........................................................ 1,290.00 1 OP

107

✔ Pegasys ✔ Pegasys ✔ Pegasys RBV Combination Pack ✔ Pegasys RBV Combination Pack

➽ SA14001365 Special Authority for Subsidy Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both: 1. Any of the following: 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and 2. Maximum of 48 weeks therapy. Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml. Renewal application — (Chronic hepatitis C – genotype 1 infection) from gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for patients meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has had previous treatment with pegylated interferon and ribavirin; and 3 Either: 3.1 Patient has responder relapsed; or 3.2 Patient was a partial responder; and 4 Patient is to be treated in combination with boceprevir; and 5 Maximum of 48 weeks therapy. Initial application (Chronic Hepatitis C – genotype 1 infection treatment more than 4 years prior) from a gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for patients meeting the following criteria: All of the following 1. Patient has chronic hepatitis C, genotype 1; and continued... 2. Patient has had previous treatment with pegylated interferon and ribavirin; and

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

23


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

continued... 3. Any of the following: 3.1. Patient has responder relapsed; or 3.2. Patient was a partial responder; or 3.3. Patient received interferon treatment prior to 2004; and 4. Patient is to be treated in combination with boceprevir; and 5. Maximum of 48 weeks therapy. Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1. Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2. Maximum of 6 months therapy. Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B treatment-naive; and 3 ALT > 2 times Upper Limit of Normal; and 4 HBV DNA < 10 log10 IU/ml; and 5 Either: 5.1 HBeAg positive; or 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and 6 Compensated liver disease; and 7 No continuing alcohol abuse or intravenous drug use; and 8 Not co-infected with HCV, HIV or HDV; and 9 Neither ALT nor AST > 10 times upper limit of normal; and 10 No history of hypersensitivity or contraindications to pegylated interferon; and 11 Maximum of 48 weeks therapy. Notes: Approved dose is 180 mcg once weekly. The recommended dose of Pegylated Interferon-alpha 2a Interferon alfa-2a is 180 mcg once weekly. In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferonalpha 2a Interferon alfa-2a dose should be reduced to 135 mcg once weekly. In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines. Pegylated Interferon-alpha 2a Interferon alfa-2a is not approved for use in children. 125 VENLAFAXINE – Special Authority see SA1061 – Retail pharmacy Tab 37.5 mg ............................................................................ 5.06 Tab 75 mg ................................................................................ 6.44 Tab 150 mg .............................................................................. 8.86 Tab 225 mg ............................................................................ 14.34 Cap 37.5 mg – Special Authority see SA1061 – Retail pharmacy ................................................................ 8.71 Cap 75 mg – Special Authority see SA1061 – Retail pharmacy .............................................................. 17.42 Cap 150 mg – Special Authority see SA1061 – Retail pharmacy .............................................................. 21.35 28 28 28 28 28 28 28 ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Efexor XR ✔ Efexor XR ✔ Efexor XR

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

24

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

136 RISPERIDONE – Special Authority see SA0927 – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency Tab orodispersible Orally-disintegrating tablets 0.5 mg ........... 21.42 Tab orodispersible Orally-disintegrating tablets 1 mg ............. 42.84 Tab orodispersible Orally-disintegrating tablets 2 mg ............. 85.71 CYTARABINE Inj 100 mg 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist ..................................... 55.00 80.00 Inj 1 g 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist .................................................. 8.83 42.65 Inj 2 g 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist ................................................ 17.65 34.47

28 28 28

✔ Risperdal Quicklet ✔ Risperdal Quicklet ✔ Risperdal Quicklet

148

5 1 1

✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne

204

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 0.75 KCAL/ML – Special Authority see SA1196 – Hospital pharmacy [HP3] Liquid ........................................................................................ 4.00 500 ml OP ✔ Nutrini Low Energy Multi Fibre

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

25


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 October 2013

78 88 122 CLOTRIMAZOLE ❋ Vaginal crm 1% with applicators ( subsidy) .............................. 1.45 ❋ Vaginal crm 2% with applicators ( subsidy).............................. 2.20 CEFACLOR MONOHYDRATE ( subsidy) Cap 250 mg ............................................................................ 26.00 OXYCODONE HYDROCHLORIDE ( subsidy) a) Only on a controlled drug form b) See prescribing guideline c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Tab controlled-release 10 mg .................................................... 6.75 (11.14) Tab controlled-release 20 mg ................................................. 11.50 (18.93) Tab controlled-release 40 mg ................................................. 18.50 (33.29) Tab controlled-release 80 mg .................................................. 34.00 (58.03) 35 g OP 20 g OP 100 ✔ Clomazol ✔ Clomazol ✔ Ranbaxy-Cefaclor

20 OxyContin 20 OxyContin 20 OxyContin 20 OxyContin

Effective 1 September 2013

42 42 VITAMIN B COMPLEX ( subsidy) ❋ Tab, strong, BPC ....................................................................... 4.30 ASCORBIC ACID ( subsidy) a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg .............................................................................. 7.00 VITAMINS ( subsidy) ❋ Tab (BPC cap strength) ............................................................. 7.60 POTASSIUM IODATE ( subsidy) ❋ Tab 256 mcg (150 mcg elemental iodine) ................................. 6.53 DEXTROSE WITH ELECTROLYTES ( subsidy) Soln with electrolytes ................................................................ 6.55 PINDOLOL ( subsidy) ❋ Tab 5 mg ................................................................................. 9.72 ❋ Tab 10 mg ............................................................................ 15.62 ❋ Tab 15 mg ............................................................................. 23.46 500 ✔ B-PlexADE ✔ Bplex

42 43 51

500

✔ Vitala-C ✔ Cvite ✔ MultiADE ✔ Mvite ✔ NeuroKare

1,000

90

1,000 ml OP ✔ Pedialyte – Bubblegum 100 100 100 ✔ Apo-Pindolol ✔ Apo-Pindolol ✔ Apo-Pindolol

56

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

26

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2013 (continued)

59 105 107 GEMFIBROZIL ( subsidy) ❋ Tab 600 mg ............................................................................ 17.60 60 ✔ Lipazil

LAMIVUDINE – Special Authority see SA1364 – Retail pharmacy ( subsidy) Oral liq 10 mg per ml ............................................................. 102.50 240 ml OP ✔ 3TC PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1400 – Retail pharmacy ( subsidy) See prescribing guideline Inj 180 mcg prefilled syringe .................................................. 900.00 4 ✔ Pegasys Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ............................................................................ 1,159.84 1 OP ✔ Pegasys RBV Combination Pack Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ........................................................................... 1,290.00 1 OP ✔ Pegasys RBV Combination Pack LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ( subsidy) Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO ............ 17.50 (35.00) Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO ............ 12.00 (20.00) VENLAFAXINE ( subsidy) Tab 37.5 mg ............................................................................ 5.06 Tab 75 mg ................................................................................ 6.44 Tab 150 mg ............................................................................. 8.86 Tab 225 mg ............................................................................ 14.34 CYTARABINE ( subsidy) Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist ................................................ 55.00 Inj 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist .................................................. 8.83 Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist ................................................ 17.65 Inj 1 mg for ECP – PCT only – Specialist ................................... 0.11 Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist.......................................................................... 11.00 50 Xylocaine 5 Xylocaine 28 28 28 28 ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR

119

125

148

5 1 1 10 mg

✔ Pfizer ✔ Pfizer ✔ Pfizer ✔ Baxter

100 mg OP ✔ Baxter

161

MYCOPHENOLATE MOFETIL – Special Authority see SA1041 – Retail pharmacy ( subsidy) Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ........................................................................... 25.00 50 ✔ Cellcept Cap 250 mg ........................................................................... 25.00 100 ✔ Cellcept

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

27


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 September 2013

15 “Specialist”, in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below: a) i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the prescription in the course of practising in that area of medicine; and or ii) the doctor’s vocational scope of practice is one of those listed below: — anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology; or b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of medicine; or c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine; or d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so. 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference: a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand. 3.3.2 If a Community Pharmaceutical is either: a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply,or c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule. and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

18

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

28


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 October 2013

46 58 65 SODIUM TETRADECYL SULPHATE ❋ Inj 0.5% 2 ml .......................................................................... 23.20 (51.00) ❋ Inj 1% 2 ml ............................................................................. 25.00 (55.00) CLONIDINE HYDROCHLORIDE ❋ Tab 25 mcg............................................................................. 13.47 CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail soln 8% ........................................................................... 19.85 LEVONORGESTREL ❋ Tab 750 mcg ............................................................................ 3.50 ETHINYLOESTRADIOL WITH DESOGESTREL ❋ Tab 20 mcg with desogestrel 150 mcg ..................................... 6.62 (16.50) a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 b) Up to 63 tab available on a PSO ❋ Tab 30 mcg with desogestrel 150 mcg ..................................... 6.62 (16.50) a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 b) Up to 63 tab available on a PSO 5 Fibro-vein 5 Fibro-vein 100 ✔ Dixarit

3 g OP 2 63

✔ Batrafen ✔ Next Choice

78 76

Mercilon 21 63 Marvelon 21

88

CEFOXITIN SODIUM – Retail pharmacy-Specialist – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. Inj 1 g .................................................................................... 55.00 5 ✔ Mayne CEFUROXIME SODIUM Inj 250 mg – Maximum of 3 inj per prescription; can be waived by endorsement ....................................................... 20.97 10 ✔ Mayne Waiver by endorsement must state that the prescription is for dialysis or cystic fibrosis patient. Inj 1.5 g – Retail pharmacy-Specialist – Subsidy by endorsement .................................................... 2.65 1 ✔ Mylan 4.04 ✔ Zinacef Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. FUSIDIC ACID Inj 500 mg sodium fusidate per 10 ml – Retail pharmacySpecialist – Subsidy by endorsement ................................... 12.87 1 (17.80) Fucidin Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

88

92

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

29


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 October 2013 (continued)

119 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO .............. 13.80 Inj 2%, 20 ml ampoule – Up to 5 inj available on a PSO ............ 12.00 50 5 ✔ Xylocaine ✔ Xylocaine

130

SUMATRIPTAN Tab 50 mg ............................................................................... 1.19 4 ✔ Arrow-Sumatriptan Tab 100 mg ............................................................................. 1.10 4 ✔ Arrow-Sumatriptan Note – Arrow-Sumatriptan tab 50 mg and 100 mg in 100 tab pack size remains subsidised. HOMATROPINE HYDROBROMIDE ❋ Eye drops 2% ........................................................................... 7.18 PHARMACY SERVICES ❋ Brand switch fee ....................................................................... 4.33 15 ml OP 1 fee ✔ Isopto Homatropine ✔ BSF Arrow-Quinapril

185 187

Effective 1 September 2013

31 32 107 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g × 12.7 mm ..................................................................... 10.50 100 ✔ ABM

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle ........................... 13.00 100 ✔ ABM ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle ........................... 13.00 100 ✔ ABM ❋ Syringe 0.5 ml with 31 g × 8 mm needle ................................ 13.00 100 ✔ ABM PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1365 – Retail pharmacy See prescribing guideline Inj 135 mcg prefilled syringe .................................................. 362.00 1 ✔ Pegasys Inj 180 mcg prefilled syringe ................................................. 450.00 1 ✔ Pegasys FAT SUPPLEMENT – Special Authority see SA1374 – Hospital pharmacy [HP3] Oil ........................................................................................... 28.73 250 ml OP ✔ Liquigen ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ........................................................................................ 2.65 500 ml OP ✔ Nutrison Standard RTH ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ........................................................................................ 2.65 500 ml OP ✔ Nutrison Multi Fibre

199 207

207

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

30

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 December 2013

39 MACROGOL 3350 – Special Authority see SA0891 – Retail pharmacy Powder 13.125 g, sachets – Maximum of 60 sach per prescription ......................................................................... 18.14 PHARMACY SERVICES – May only be claimed once per patient Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Acetec is 2445441

30 1 fee

✔ Movicol ✔ BSF Acetec

187

Effective 1 January 2014

59 CHLORTALIDONE [CHLORTHALIDONE] ❋ Tab 25 mg ................................................................................ 4.80 30 Note – The delist date has been extended from 1 October 2013 to 1 January 2014. ✔ Igroton S29

Effective 1 March 2014

77 NORETHISTERONE WITH MESTRANOL ❋ Tab 1 mg with mestranol 50 mcg and 7 inert tab........................ 6.62 (13.80) a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 b) Up to 84 tab available on a PSO PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN] Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO......... 315.00 AZATHIOPRINE – Retail pharmacy-Specialist ❋ Tab 50 mg – For azathioprine oral liquid formulation refer, page 189 ............................................................................. 18.45 PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN ❋ Eye oint with soft white paraffin ................................................. 3.63 84 Norinyl-1/28

90 161 186 202

10

✔ Bicillin LA

100 3.5 g OP

✔ Imuran ✔ Lacri-Lube

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (strawberry) ................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (vanilla) .......................................................................... 1.07 200 ml O ✔ Pediasure 1.27 237 ml OP ✔ Pediasure Note – Replacement Pediasure packs were listed 1 September 2013.

Effective 1 April 2014

131 ✔ Dr Reddy’s Ondansetron Note – Dr Reddy's Ondansetron tab dispersible 4 mg in the 100 pack size remains subsidised. CYCLOPHOSPHAMIDE Tab 50 mg – PCT – Retail pharmacy-Specialist........................ 25.71 50 ✔ Cycloblastin ONDANSETRON ❋ Tab disp 4 mg .......................................................................... 0.68 4

147

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

31


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 April 2014 (continued)

177 BUDESONIDE Powder for inhalation, 200 mcg per dose ................................ 15.20 Powder for inhalation, 400 mcg per dose ................................ 25.60 200 dose OP ✔ Budenocort 200 dose OP ✔ Budenocort

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

32

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Index

Pharmaceuticals and brands Symbols 3TC ................................................................... 27 A Acetec ................................................... 20, 21, 22 Aclasta .............................................................. 21 Apo-Perindopril .................................................. 21 Apo-Pindolol ...................................................... 26 Apresoline s29 ................................................... 18 Arrow - Clopid.................................................... 18 Arrow-Sumatriptan ............................................. 30 Arrow-Venlafaxine XR................................... 24, 27 Ascorbic acid ..................................................... 26 Azathioprine ....................................................... 31 B Batrafen ............................................................. 29 Bicillin LA........................................................... 31 Boceprevir ......................................................... 19 Bplex ................................................................. 26 B-PlexADE ......................................................... 26 BSF Acetec .................................................. 20, 31 BSF Arrow-Quinapril ........................................... 30 Budenocort ........................................................ 32 Budesonide ........................................................ 32 C Cefaclor monohydrate ........................................ 26 Cefoxitin sodium ................................................ 29 Cefuroxime sodium ............................................ 29 Cellcept ............................................................. 27 Chlortalidone [chlorthalidone] ............................. 31 Ciclopirox olamine.............................................. 29 Clomazol............................................................ 26 Clonidine hydrochloride ...................................... 29 Clopidogrel ........................................................ 18 Clotrimazole ....................................................... 26 Coversyl ............................................................ 21 Cvite .................................................................. 26 Cycloblastin ....................................................... 31 Cyclophosphamide ...................................... 18, 31 Cytarabine ................................................... 25, 27 D Dr Reddy’s Ondansetron .................................... 31 Desmopressin .................................................... 19 Dextrose with electrolytes................................... 26 Dixarit ................................................................ 29 E Efexor XR ........................................................... 24 Efexor XR ........................................................... 24 Enalapril maleate .............................. 18, 20, 21, 22 Enteral feed 1kcal/ml .......................................... 30 Enteral feed with fibre 1 kcal/ml .......................... 30 Ethics Enalapril ............................................ 18, 21 Ethinyloestradiol with desogestrel ....................... 29 F Fat supplement .................................................. 30 Fibro-vein........................................................... 29 Fucidin ............................................................... 29 Fusidic acid........................................................ 29 G Gemfibrozil ........................................................ 27 Genox ................................................................ 19 H Homatropine hydrobromide ................................ 30 Hydralazine hydrochloride .................................. 18 Hyoscine (scopolamine)..................................... 21 Hyoscine hydrobromide ..................................... 21 I Igroton ............................................................... 31 Imuran ............................................................... 31 Insulin pen needles............................................. 30 Insulin syringes, disposable with attached needle ............................................... 30 Interferon alfa-2a................................................ 22 Interferon alfa-2b ............................................... 23 Interferon alpha-2a ............................................. 22 interferon alpha-2b ............................................. 23 Imipramine hydrochloride ................................... 20 Intron-A ............................................................. 23 Isopto Homatropine ............................................ 30 L Lacri-Lube ......................................................... 31 Lamivudine ........................................................ 27 Levonorgestrel ................................................... 29 Lidocaine [lignocaine] hydrochloride ............ 27, 30 Lipazil ................................................................ 27 Liquigen ............................................................. 30 Lorafix ............................................................... 19 Loratadine.......................................................... 19 Ludiomil s29 ...................................................... 18 M Macrogol 3350 .................................................. 31 Maprotiline hydrochloride ................................... 18 Marvelon 21....................................................... 29 m-Enalapril .................................................. 21, 22 Mercilon 21 ....................................................... 29 Mesalazine ......................................................... 19 Minirin ............................................................... 19 Movicol.............................................................. 31 MultiADE............................................................ 26 Mvite ................................................................. 26 Mycophenolate mofetil ....................................... 27 N NeuroKare.......................................................... 26

33


Index

Pharmaceuticals and brands Next Choice ....................................................... 29 Norethisterone with mestranol ............................ 31 Norinyl-1/28 ...................................................... 31 Nutrini Low Energy Multi Fibre ............................ 25 Nutrison Multi Fibre ............................................ 30 Nutrison Standard RTH....................................... 30 O Ondansetron ...................................................... 31 Oxycodone hydrochloride ............................. 21, 26 OxyContin .......................................................... 26 OxyNorm ........................................................... 21 P Paediatric enteral feed with fibre 0.75 Kcal/ml..... 25 Paediatric enteral feed with fibre 0.76 kcal/ml ..... 25 Paediatric oral feed 1kcal/ml......................... 20, 31 Paraffin liquid with soft white paraffin ........... 20, 31 Pedialyte – Bubblegum ....................................... 26 Pediasure..................................................... 20, 31 Pegasys............................................................. 23 Pegasys................................................. 23, 27, 30 Pegasys RBV Combination Pack .................. 23, 27 Pegylated interferon alfa-2a .................... 23, 27, 30 Pegylated interferon alpha-2a ............................. 23 Penicillin g benzathine [benzathine benzylpenicillin] ............................ 31 Pentasa ............................................................. 19 Perindopril ......................................................... 21 Pharmacy services................................. 20, 30, 31 Pindolol ............................................................. 26 Potassium iodate ............................................... 26 Procytox ............................................................ 18 R Ranbaxy-Cefaclor............................................... 26 Refresh Night Time ............................................ 20 Rilutek ............................................................... 18 Riluzole .............................................................. 18 Risedronate Sandoz ........................................... 20 Risedronate sodium ........................................... 20 Risperdal Quicklet .............................................. 25 Risperidone........................................................ 25 Roferon-A .......................................................... 22 S Scopoderm TTS ................................................. 21 Sodium tetradecyl sulphate ................................ 29 Sumatriptan ....................................................... 30 Synacthen.................................................... 19, 22 T Tamoxifen citrate................................................ 19 Tamsulosin hydrochloride .................................. 18 Tamsulosin-Rex ................................................. 18 Tepadina ............................................................ 20 Tetracosactrin .............................................. 19, 22 Thiotepa............................................................. 20 Tofranil S29 ....................................................... 20 V Venlafaxine .................................................. 24, 27 Victrelis.............................................................. 19 Vitala-C .............................................................. 26 Vitamin B complex ............................................. 26 Vitamins ............................................................ 26 X Xylocaine ..................................................... 27, 30 Z Zoledronic acid .................................................. 21

34


Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 October 2013

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 October 2013 Cumulative for September and October 2013 Contents Summary of PHARMAC decisions effective 1 October 2013 ….. 3 New treatment for amyotrophic lateral sclerosis (motor neurone disease)…. 4 Further…

Page 1

icon

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.